Covidien Announces CE Mark for Nellcor™ Respiration Rate Software


Covidien, a household name in medical devices and recognized innovator in patient monitoring and respiratory care equipment, has attained CE Mark approval for its Nellcor™ Respiration Rate Version 1.0 Software and the Adult Respiration Rate Sensor.  This means its new respiratory monitoring platform can now be made available throughout the European Economic Area (EEA).

According to the news release the company plans a limited market release starting in January 2012, and will allow select European hospitals to be the first to use the new technology.


The Covidien Nellcor Respiration Rate software derives a patient’s respiration rate from changes in the pulse oximetry signal that occur as a result of breathing. By adding Respiration Rate functionality to its software Covidien claims to be providing clinicians with a more holistic view of the patient’s respiratory status.

Company comments 

“Respiration rate is a critical vital sign that can provide an early warning of respiratory complications that may require immediate intervention,” said Scott Kelley, M.D., Chief Medical Officer, Respiratory and Monitoring Solutions, Covidien.

“Despite its clinical importance, current methods of respiration rate monitoring are not always adequate. The addition of Respiration Rate to the Covidien Nellcor Respiratory Function portfolio provides a more holistic monitoring solution using a single, integrated sensor. Instead of merely knowing a patient’s blood oxygen levels, we can now look at aspects of ventilation, or the passing of air into and out of the body. This gives dedicated care teams a more complete picture of a patient’s respiratory status, so they can provide effective treatment and maintain patient safety.”

“We are pleased to CE Mark the new Covidien Nellcor Respiration Rate software and sensor. We believe this technology offers significant advancements in patient monitoring,” said Robert White, President, Respiratory and Monitoring Solutions. “This important milestone reflects Covidien’s commitment to making investments in clinically relevant product innovations designed to improve patient outcomes.”

Source: Businesswire, Covidien